0000000000711636

AUTHOR

Jae-yong Kwak

showing 2 related works from this author

149. Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A…

2018

Abstract Background Patients with hematologic malignancies treated with anticancer immunosuppressive therapies (ITs) are at increased risk of herpes zoster (HZ). In a previous report of this phase 3, observer-blind, multicenter trial (NCT01767467), the adjuvanted recombinant zoster vaccine (RZV) was shown to be immunogenic and well-tolerated in ≥18 years of age patients with hematologic malignancies who completed or were undergoing anticancer IT.1 Here we report end-of-study results from the same trial. Methods Participants were randomized 1:1 to receive 2 doses of RZV or placebo (PL) 1–2 months apart, either ≥10 days before or after a cancer therapy cycle, or 10 days to 6 months after canc…

0301 basic medicinemedicine.medical_specialtyPost hocbusiness.industryImmunogenicityCancer therapyHematologic Neoplasmslaw.invention03 medical and health sciencesAbstracts030104 developmental biology0302 clinical medicineInfectious DiseasesOncologyRandomized controlled triallawA. Oral AbstractsInternal medicineRecombinant DNAMedicineZoster vaccine030212 general & internal medicineAdverse effectbusinessmedicine.drugOpen Forum Infectious Diseases
researchProduct

Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation A Randomized Clinical Trial

2019

###EgeUn###

AdultMalemedicine.medical_specialtyHerpes Zoster Vaccinemedicine.medical_treatmentvirusesVaccines Synthetic/administration & dosageHematopoietic stem cell transplantationPlaceboInjections IntramuscularTransplantation Autologous01 natural sciencesHerpes Zoster Vaccine/administration & dosage03 medical and health sciences0302 clinical medicineAutologous stem-cell transplantationAdjuvants ImmunologicInternal medicinehemic and lymphatic diseasesmedicineHumansSingle-Blind Method030212 general & internal medicine0101 mathematicsAdverse effectHospitalization/statistics & numerical dataProportional Hazards ModelsImmunocompromised hostintegumentary systembusiness.industryIncidence (epidemiology)010102 general mathematicsvirus diseasesGeneral MedicineMiddle AgedNeuralgia Postherpetic/prevention & controlTransplantationsurgical procedures operativeHerpes Zoster/epidemiologyhematopoietic stem cell transplantationoncologyincidenceFemaleZoster vaccinebusinessFollow-Up Studiesmedicine.drug
researchProduct